Spanish colorectal surgery up

RNS Number : 3775Z

Deltex Medical Group PLC

21 September 2009

 



Deltex Medical Group plc

Spanish colorectal surgery update

21 September 2009 - Deltex Medical Group plc ('Deltex Medical' 'Company' or 'Group'), the global leader in oesophageal Doppler monitoring ('ODM'), today announces the latest results from a major audit of the effect of implementation of its CardioQ-ODM™ system within enhanced recovery surgery in Spain.

At the HAI meeting in Berlin, Dr Ramirez of the University Hospital of Zaragoza, one of Spain's leading colorectal surgeons presented an update on the project to introduce enhanced recovery colorectal surgery as a standard of care in Spain. The enhanced recovery protocol being followed has 14 individual steps including 'Goal directed fluid therapy (CardioQ)'.

Data on the first 234 patients from the 10 participating hospitals shows average length of stay in hospital reduced from 13 days to seven.

Following detailed analysis of their relative benefit, six of the 14 steps are now 'recommended', four steps are 'highly recommended' and use of CardioQ-ODM to guide intravascular fluids is now one of four 'mandatory' steps. This means that any of the new hospitals looking to join the project, as well as current participants, must use the CardioQ-ODM on 100% of colorectal patients treated within the enhanced recovery programme.

The Spanish enhanced recovery programme's website is www.ftsurgery.com. 

Ewan Phillips, Deltex Medical's chief executive, commented:

'This is the first time that such a large group of hospitals have agreed to mandate the use of CardioQ-ODM in colorectal surgery. CardioQ-ODM is increasingly widely recognised as a standard of care in both colorectal surgery and enhanced recovery surgery programmes: this is a key step towards translating this recognition into wide-scale routine usage.'

For further information, please contact:-

Deltex Medical Group plc            01243 774 837

Nigel Keen, Chairman                    [e-mail]

Ewan Phillips, Chief Executive        [e-mail]

Paul Mitchell, Finance Director        [e-mail]

Nominated Adviser & Broker

Arden Partners plc                020 7398 1600

Chris Hardie                           [e-mail]

Matthew Armitt                       [e-mail]

Kreab Gavin Anderson        020 7554 1400

Deborah Walter                     [e-mail]

Robert Speed                        [e-mail]

  Notes for Editors

Deltex Medical manufactures and markets the CardioQ-ODM™ monitor, which uses disposable ultra-sound probes inserted into the oesophagus to determine the amount of blood being pumped around the body - 'circulating blood volume'. Reduced circulating blood volume is known as hypovolaemia, which leads to insufficient oxygen being delivered to the organs. This causes medical complications including peripheral and major organ failure which can lead to death. Hypovolaemia, which is akin to severe dehydration, affects virtually every patient having surgery because of the combined effects of pre-operative starvation, the impact of the anaesthetic agents and trauma from the surgery itself. Using fluids and drugs, guided by the CardioQ-ODM, to optimise the amount of circulating blood significantly reduces post-operative complications allowing patients to make a faster, more complete recovery and return home earlier.

The CardioQ-ODM incorporates the Company's proprietary software and a small diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is used for transmitting and receiving an ultra-sound signal. By using this technology, the CardioQ-ODM provides clinicians with the ability to haemodynamically optimise critically ill patients and those undergoing routine moderate to major surgery through the controlled administration of fluid and drugs. Haemodynamic optimisation has been scientifically proven to improve the speed and quality of patient recovery and reduce hospital stay.

There are already over 1,750 CardioQ-ODMs currently in use in hospitals worldwide and distribution arrangements are in place in over 30 countries. In addition, there are currently more than 200 clinical publications on the use of the CardioQ-ODM which have repeatedly:-

• Validated the results of the Monitor against known standards for measuring cardiac output, demonstrating that the technology works

• Proved that the CardioQ-ODM works in a wide range of surgical procedures

• Demonstrated that the Company's technology provides significant health and economic benefits by helping to reduce post-operative complications and length of hospital stays by an average of 30 to 40 per cent for a wide range of patients.

The SupraQ™ is an entirely non-invasive device which uses an ultrasound probe held at the base of the patient's neck to track the flow of blood in the aorta; it presents the same data as the CardioQ-ODM in a similar format and is used for taking snapshots or monitoring over short periods.

 

END

 

 

NRAUAVKRKVRKURR